Hostname: page-component-7f64f4797f-l842n Total loading time: 0 Render date: 2025-11-08T01:59:38.416Z Has data issue: false hasContentIssue false
Accepted manuscript

Psilocybin-Assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: Protocol for a Randomised Dose-Comparison Pilot Study

Published online by Cambridge University Press:  04 November 2025

Chiranth Bhagavan*
Affiliation:
Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC, Australia
Alexander Bryson*
Affiliation:
Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia Department of Neurology, Melbourne Health, Parkville, VIC, Australia Department of Neurology, Eastern Health, Box Hill, VIC, Australia
Olivia Carter
Affiliation:
Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC, Australia
Glenn Nielsen
Affiliation:
Neurosciences and Cell Biology Research Institute, St George’s University of London, London, United Kingdom
David Berlowitz
Affiliation:
Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia Department of Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, Carlton, VIC, Australia
Sara Issak
Affiliation:
Department of Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, Carlton, VIC, Australia Department of Physiotherapy, Epworth Healthcare, Camberwell, VIC, Australia
Sabine Braat
Affiliation:
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia MISCH (Methods and Implementation Support for Clinical Health) Research Hub, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia
Sophie Zaloumis
Affiliation:
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia MISCH (Methods and Implementation Support for Clinical Health) Research Hub, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia
Zachary Attard
Affiliation:
Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia Department of Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, Carlton, VIC, Australia
Dina Eleftheriadis
Affiliation:
Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC, Australia
Georgina Oliver
Affiliation:
Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC, Australia
Deanne Mayne
Affiliation:
FND Hope International, Salmon, Idaho, United States
Greg Roebuck
Affiliation:
Phoenix Australia, Centre for Posttraumatic Mental Health, Department of Psychiatry, The University of Melbourne, Carlton, VIC, Australia The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, and Barwon Health, Geelong, VIC, Australia
James Rucker
Affiliation:
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom South London & Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom
Matthew Butler
Affiliation:
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom South London & Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom
Richard Kanaan
Affiliation:
Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC, Australia Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia
*
*Corresponding authors: Dr Chiranth Bhagavan Email: cbhagavan@student.unimelb.edu.au Phone: (+61)493766597 Address: Department of Psychiatry, University of Melbourne, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Dr Alexander Bryson Email: alexander.bryson@florey.edu.au Address: Florey Institute of Neuroscience & Mental Health, 30 Royal Parade, Parkville VIC 3052, Australia
*Corresponding authors: Dr Chiranth Bhagavan Email: cbhagavan@student.unimelb.edu.au Phone: (+61)493766597 Address: Department of Psychiatry, University of Melbourne, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Dr Alexander Bryson Email: alexander.bryson@florey.edu.au Address: Florey Institute of Neuroscience & Mental Health, 30 Royal Parade, Parkville VIC 3052, Australia
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are no effective pharmacotherapies, and despite the early promise of physiotherapy studies, many suffer disabling symptoms in the long term. There is a theoretical rationale for combining psychedelics with physiotherapy; however, the potential benefit of this approach and optimal treatment model remains unexplored. Here, we present the protocol for the first study investigating the tolerability, feasibility, and potential efficacy of two distinct treatment regimens of psilocybin-assisted physiotherapy for refractory motor FND: a moderate dose that incorporates movement tasks during the acute drug effects versus a standard dose alone.

Methods:

Twenty-four participants with refractory motor FND will be randomised in a 1:1 ratio to either (1) psilocybin 15mg, with movement tasks conducted during the acute drug effects; or (2) psilocybin 25mg alone. All participants will receive two sessions of FND-specific physiotherapy pre-dosing, six sessions of physiotherapy post-dosing, and undergo follow-up visits one week and four weeks following their final physiotherapy session. A battery of outcome measures will be completed as scheduled, assessing tolerability, feasibility, motor FND symptom severity, psychiatric and physical symptoms, quality of life, treatment expectations, intensity of the acute drug effects, personality, motor function, force-matching performance, resting-state and task-based brain imaging, and subjective experiences of the study treatment.

Discussion:

These findings will assist the design of an adequately powered randomised controlled trial in this cohort. The findings may also inform the feasibility of psychedelic treatment in related functional and neuropsychiatric disorders.

Information

Type
Protocol
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology